Executive Team

Dr. Abraham is CEO and co-founder of NeuraWell, a mental health therapeutics company.  He co-founded ‘ComScore’ and took it public in 2007. He was founder and CEO of Paragren Technologies, producing CRM systems. As president of IRI, a major international research company, he led the company through sustained growth and innovation.

Dr. Abraham received a Ph.D. and an M.B.A. from MIT, and is Engineer of the Ecole Polytechnique, France.  He became a Visiting Scholar at Stanford in 2015, where he taught at the Graduate School of Business for three years. He serves on several commercial and institutional boards.

He is a world expert on consumer and market measurement and analytics and has authored seminal award-winning articles.  He received some of the most prestigious awards in the field. He was inducted in the Entrepreneurship Hall of Fame and designated “Technology Pioneer” by the World Economic Forum.

Dr. Stahl has held faculty positions at Stanford University, the University of California at Los Angeles, the Institute of Psychiatry London, the Institute of Neurology London, and, currently, as clinical professor of psychiatry and neuroscience at the University of California Riverside, adjunct professor of psychiatry at the University of California San Diego and as Honorary Fellow in Psychiatry at the University of Cambridge. Dr. Stahl serves as editor-in-chief of CNS Spectrums and is Senior Academic Advisor and Director of Psychopharmacology for the California Department of State Hospitals (DSH) where he has a leadership role in addressing violence and decriminalization of the seriously mentally ill in the five-hospital 6500 patient DSH.

Author of over 560 articles and chapters with an H index of 62, and more than 2000 scientific presentations and abstracts, Dr. Stahl is an internationally renowned clinician, researcher, and teacher in psychiatry with subspecialty expertise in psychopharmacology.  Dr. Stahl has written 53 textbooks and edited 15 others, including the best-selling and award winning textbook, Stahl’s Essential Psychopharmacology, now in its fifth edition and the best-selling and award-winning clinical manual, Essential Psychopharmacology Prescriber’s Guide, now in its seventh edition.  Dr. Stahl has also published a novel, Shell Shock, a thriller that recounts the history of PTSD (post-traumatic stress disorder).

Laurel is a clinical research professional who received her BA in Behavioral Science and Law from the University of Wisconsin, Madison. She began her career supporting academic research efforts studying and developing the innovative, local psychiatric community support programs. She subsequently transitioned into clinical research at the University of Wisconsin Hospital as a Study Coordinator in the Department of Psychiatry. She has extensive and broad experience in site monitoring and management, clinical operations, clinical project and program management in Phases I-IV clinical trials, and clinical development. She has worked within pharmaceutical and CRO organizations managing both early and late phase, fully insourced and outsourced complex clinical trials. Prior to starting her consulting firm, she held senior level program management and head of clinical operations positions for biopharmaceutical companies focusing on central nervous system drug development. She has led and implemented early phase (first in human to proof of concept) as well as successful registrational clinical development programs throughout her career.

Ms. Goodhead received a B.S. degree in chemistry from the University of South Florida and a Master’s degree in science from the University of Tampa. She has more than 20 years of experience in the pharmaceutical industry. Ms. Goodhead is President of Pharmaceutical Project Solutions, a pharmaceutical drug development consulting firm. Prior to starting her consulting firm, Ms. Goodhead held a senior management position at Somerset Pharmaceuticals, where she was responsible for development, manufacturing and regulatory strategy. She played a key role in the development and regulatory approval of a novel, next generation MAO inhibitor (patch selegiline) for the treatment of depression, Parkinson’s disease and other indications. Ms. Goodhead has led multiple successful 505(b)(1) and 505(b)(2) applications and filed multiple INDs, in multiple Divisions. In addition, Ms. Goodhead had led, and presented in, industry focused FDA Advisory Committee meetings responsible for data preparation, response development, and presentation format. She played the led role in label, patient information and REMS development, negotiation and positioning. Ms. Goodhead is responsible for regulatory and compliance at EPI HEALTH.

Dr. Satterly leads Research & Development at NeuraWell, where she provides scientific, strategic, and operational direction to expand and progress NeuraWell pipeline opportunities. She received a B.S. in Chemistry from the University of Puget Sound and a PhD in Medicinal Chemistry from the University of Washington, where she studied drug metabolism, pharmacokinetics, and bioanalytical chemistry. Following graduate training, Dr. Satterly joined startup pharmaceutical companies to discover and develop treatments for CNS diseases. She has held leadership positions and worn many hats at numerous startups from seed to IPO stages with a focus on providing innovative solutions and integrated programming to the discovery and development of novel therapeutics. Prior to joining NeuraWell, Dr. Satterly’s recent positions included Vice President of Research & Development at Field Trip (now Reunion Neuroscience) where she focused on the discovery and development of novel 5-HT2A agonists, and Senior Director of Drug Research & Development at Impel NeuroPharma where she led development of novel 505(b)(2) drug-device combination products for migraine, agitation in schizophrenia, and Parkinson’s disease and played a key role in development and ultimate FDA approval of Impel’s Trudhesa product.

Prior to joining NeuraWell, Katherine was Vice President of Clinical Development at Neumora Therapeutics, a position she held since 2020 while at BlackThorn Therapeutics which Neumora acquired. There she led and expanded clinical development and clinical operations teams to support several Phase 1 through Phase 2 programs.

She has held leadership positions at several biopharmaceutical companies, including, Executive Director, Clinical Development at Avanir Pharmaceuticals (2017-2020), Senior Medical Director at Astellas (2013-2017), Vice President Clinical Research Ovation Pharmaceuticals (subsequently acquired by Lundbeck) (2004-2008), Abbvie (2008-2013) and Abbott (1998-2004). She has held positions of increasing responsibility for medical, safety and scientific aspects of development programs spanning Phase 1 through 4 in psychiatry (e.g., major depressive disorder, bipolar disorder, intermittent explosive disorder, agitation in Alzheimer’s disease, psychosis in Parkinson’s disease), in seizure disorders, and in pain indications (osteoarthritis, fibromyalgia).

Prior to joining the pharmaceutical industry, Katherine was an Assistant Professor Psychiatry at the University of Illinois. She received her medical degree and completed her residency in psychiatry at Rush Medical College in Chicago. Prior to medical school, she obtained a PhD in psychology at the University of California, Santa Barbara.